ConductScience.org, home

Disease · MONDO_0005607

Drugs45

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

DrugChEMBL IDTypeOpen Targets' stageStage reported byReportsOf them trialsTrials shown hereSource
ROFLUMILASTCHEMBL193240Small moleculeApprovalDailyMed877Drugs and targets
LEVOFLOXACINCHEMBL5315124Small moleculeApprovalDailyMed433Drugs and targets
AZITHROMYCINCHEMBL529Small moleculeApprovalDailyMed422Drugs and targets
CLARITHROMYCINCHEMBL1741Small moleculeApprovalDailyMed311Drugs and targets
CEFACLORCHEMBL1201018Small moleculeApprovalDailyMed211Drugs and targets
CEFUROXIME AXETILCHEMBL1095930Small moleculeApprovalDailyMed211Drugs and targets
FLUTICASONE PROPIONATECHEMBL1473Small moleculeApprovalDailyMed211Drugs and targets
SALMETEROL XINAFOATECHEMBL1082607Small moleculeApprovalDailyMed211Drugs and targets
MOXIFLOXACIN HYDROCHLORIDECHEMBL1200735Small moleculeApprovalDailyMed1800Drugs and targets
CEFDINIRCHEMBL927Small moleculeApprovalDailyMed800Drugs and targets
GLYCOPYRRONIUM BROMIDECHEMBL1201027Small moleculeApprovalDailyMed and PMDA400Drugs and targets
TIOTROPIUM BROMIDECHEMBL3545181Small moleculeApprovalDailyMed400Drugs and targets
FORMOTEROL FUMARATECHEMBL3989798Small moleculeApprovalDailyMed300Drugs and targets
CEFDITOREN PIVOXILCHEMBL454446Small moleculeApprovalDailyMed200Drugs and targets
CEFIXIMECHEMBL1541Small moleculeApprovalDailyMed200Drugs and targets
INDACATEROL MALEATECHEMBL1789842Small moleculeApprovalDailyMed and PMDA200Drugs and targets
IPRATROPIUM BROMIDECHEMBL2134724Small moleculeApprovalDailyMed200Drugs and targets
TELITHROMYCINCHEMBL1136Small moleculeApprovalEMA Human Drugs, at withdrawal200Drugs and targets
THEOPHYLLINECHEMBL1355736ProteinApprovalDailyMed200Drugs and targets
ACLIDINIUM BROMIDECHEMBL551466Small moleculeApprovalFDA100Drugs and targets

diseases-2026-09-18-0.1.0

Sources 6

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • NLM's MeSHNLM's terms
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • NLM's MeSHNLM's
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005607/drugs